Digital Pharma China

Even in the short time since the last year’s event, much has changed in the Chinese market. 2016 is the perfect time to advocate for digital approaches within pharmaceutical organizations.
On a macro level, new governmental policy is limiting the prices pharma organizations are able to charge for their drugs, and the government is trying to tightly control insurance coverage. As such, insurance policies are much stricter, and pharma is feeling the pressure. With decreased margins leading to less money to spend on marketing communications, having a larger sales force is no longer a competitive advantage. This has been the first year of single-digit growth in China — is this the new norm? No matter what, pharma is readily adopting new digital ideas and innovations for channel management and improvements to sales teams’ effectiveness.
Patient centricity has become a core tactic for pharmaceutical companies due to this increased pressure — and is no longer purely a corporate image tool. New strategies to increase drug adherence and the development of more direct tools for patients is paramount, and digital is the key medium for improving this.
The 4th Digital Pharma China event will provide you with the road map to delivering true customer centricity and an experience that connects them to your brand. To transition from an assets company to a solutions provider, pharma organizations need to address a very important question: How can you launch for a solution, not just a product?